Bupropion for Interferon-Alpha-Induced Depression in Patients with Hepatitis C Viral Infection: An Open-Label Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Interferon (IFN)-α therapy for chronic hepatitis C virus (HCV) infection is frequently associated with major depressive episodes. Bupropion, a commonly used antidepressant agent, has recently found to have strong anti-inflammatory effects in animal models. Despite of the theoretical relevancy, the antidepressant effect of bupropion in IFN-alpha-induced depression has never been studied. Ten HCV patients with IFN-α-induced depression were recruited to receive 8-week bupropion treatment and were assessed every 2 weeks for depressive symptoms by the Hamilton rating scale for depression (HAMD) and somatic symptoms by the Neurotoxicity Rating Scale (NRS). Four of the 10 patients met the criteria for remission (total HAMD scores≤7), and 5 patients met the criteria for response (at least 50% reduction in total HAMD scores). In addition, 5 patients had 50% decreases in NRS for neuropsychiatric symptoms. This preliminary open-label study suggests that bupropion is effective in treating IFN-alpha-induced depressive and somatic symptoms.
Abstract
Interferon (IFN)-α therapy for chronic hepatitis C virus (HCV) infection is frequently associated with major depressive episodes. Bupropion, a commonly used antidepressant agent, has recently found to have strong anti-inflammatory effects in animal models. Despite of the theoretical relevancy, the antidepressant effect of bupropion in IFN-alpha-induced depression has never been studied. Ten HCV patients with IFN-α-induced depression were recruited to receive 8-week bupropion treatment and were assessed every 2 weeks for depressive symptoms by the Hamilton rating scale for depression (HAMD) and somatic symptoms by the Neurotoxicity Rating Scale (NRS). Four of the 10 patients met the criteria for remission (total HAMD scores≤7), and 5 patients met the criteria for response (at least 50% reduction in total HAMD scores). In addition, 5 patients had 50% decreases in NRS for neuropsychiatric symptoms. This preliminary open-label study suggests that bupropion is effective in treating IFN-alpha-induced depressive and somatic symptoms.
참고문헌 (13)
- Su KP, "Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a ‘mind-body interface’?", Neurosignals, 17, pp.144~152 (2009)
- Su KP, "Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels", Biol Psychiatry, 67, pp.550~557 (2010)
- Capuron L, "Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions", Neuropsychopharmacology, 26, pp.643~652 (2002)
- Kraus MR, "Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study", Gut, 57, pp.531~536 (2008)
- Wu PL, "Manic episode associated with citalopram therapy for interferon-induced depression in a patient with chronic hepatitis C infection", Gen Hosp Psychiatry, 29, pp.374~376 (2007)
- Asnis GM, "Interferon-induced depression: strategies in treatment", Prog Neuropsychopharmacol Biol Psychiatry, 29, pp.808~818 (2005)
- Fava M, "15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL", Prim Care Companion J Clin Psychiatry, 7, pp.106~113 (2005)
- Seo HJ, "An open-label, rater-blinded, 8-week trial of bupropion hydrochloride extended-release in patients with major depressive disorder with atypical features", Pharmacopsychiatry, 46, pp.221~226 (2013)
- Pae CU, "Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion", Expert Rev Neurother, 7, pp.1251~1263 (2007)
- Brustolim D, "A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice", Int Immunopharmacol, 6, pp.903~907 (2006)
- Loftis JM, "Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C", Neurosci Lett, 365, pp.87~91 (2004)
- Ahmed F, "Seizures during pegylated interferon and ribavirin therapy for chronic Hepatitis C: observations from the WIN-R trial", J Clin Gastroenterol, 45, pp.286~292 (2011)
- Su KP, "Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial", Biol Psychiatry, 76, pp.559~566 (2014)